09:52 AM EDT, 07/10/2025 (MT Newswires) -- Ascentage Pharma ( AAPG ) said Thursday that lisaftoclax has been approved by China's National Medical Products Administration for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy, including Bruton's tyrosine kinase inhibitors.

Lisaftoclax is the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for the treatment of patients with the disease in China, the company said.

The approval is based on a mid-stage study in which the treatment met its target overall response rate while also demonstrating efficacy and a favorable safety profile, Ascentage said.

Price: 42.34, Change: +0.47, Percent Change: +1.12